ITPRIPL1 and thyroid gland carcinoma: We observed the mRNA expression levels of ITPRIPL1 varied significantly across clinicopathological stages in mesothelioma (MESO), LIHC, SKCM, thyroid carcinoma (THCA), and TGCT (Figure 1E) (P < 0.05).